Virios Therapeutics, Inc. (NASDAQ:VIRI – Get Free Report) shares rose 14.2% during mid-day trading on Monday . The company traded as high as $2.70 and last traded at $2.65. 135,376 shares were traded during trading, a decline of 87% from the average daily volume of 1,049,645 shares. The stock had previously closed at $2.32.
Virios Therapeutics Stock Up 14.2%
The stock has a market cap of $51.03 million, a PE ratio of -9.81 and a beta of 1.58. The company’s fifty day moving average is $1.75 and its 200 day moving average is $2.00.
Virios Therapeutics Company Profile
Virios Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for fibrotic diseases. The company leverages its proprietary small-molecule platform to identify and advance compounds designed to modulate key pathways involved in scar formation and tissue repair. By concentrating on conditions with high unmet medical need, Virios aims to improve patient outcomes through more effective and safer treatment options.
The company’s lead development candidate, VTI-1002, is an oral small molecule inhibitor in clinical trials for the prevention and treatment of hypertrophic scars and keloids.
Further Reading
- Five stocks we like better than Virios Therapeutics
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
